GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Crescita Therapeutics Inc (TSX:CTX) » Definitions » Gross Profit

Crescita Therapeutics (TSX:CTX) Gross Profit : C$9.67 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Crescita Therapeutics Gross Profit?

Crescita Therapeutics's gross profit for the three months ended in Sep. 2024 was C$1.97 Mil. Crescita Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was C$9.67 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Crescita Therapeutics's gross profit for the three months ended in Sep. 2024 was C$1.97 Mil. Crescita Therapeutics's Revenue for the three months ended in Sep. 2024 was C$3.59 Mil. Therefore, Crescita Therapeutics's Gross Margin % for the quarter that ended in Sep. 2024 was 54.73%.

Crescita Therapeutics had a gross margin of 54.73% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 10 years, the highest Gross Margin % of Crescita Therapeutics was 74.03%. The lowest was 33.36%. And the median was 59.72%.

Warning Sign:

Crescita Therapeutics Inc gross margin has been in long-term decline. The average rate of decline per year is -4.5%.


Crescita Therapeutics Gross Profit Historical Data

The historical data trend for Crescita Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescita Therapeutics Gross Profit Chart

Crescita Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.54 11.27 10.01 13.18 10.36

Crescita Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 3.06 2.41 2.24 1.97

Competitive Comparison of Crescita Therapeutics's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescita Therapeutics's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's Gross Profit falls into.



Crescita Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Crescita Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=17.522 - 7.158
=10.36

Crescita Therapeutics's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=3.594 - 1.627
=1.97

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$9.67 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Crescita Therapeutics's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=1.97 / 3.594
=54.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Crescita Therapeutics  (TSX:CTX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Crescita Therapeutics had a gross margin of 54.73% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Crescita Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of Crescita Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Crescita Therapeutics Business Description

Traded in Other Exchanges
Address
2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada.
Executives
Daniel Chicoine Director, Senior Officer
Jose Darocha Director, Senior Officer
Serge Verreault Senior Officer
Anthony Edward Dobranowski Director
Knight Therapeutics Inc. 10% Security Holder

Crescita Therapeutics Headlines

No Headlines